Successful Treatment of Metastatic Glucagonoma With Dacarbazine

Kurose, T.; Seino, Yutaka; Ishida, Hideyuki; Fujita, Jun; Taminato, Tomohiko; Matsukura, Masaharu; Imura, Hiroo

doi:10.1016/s0140-6736(84)91011-0

Cited by 20 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported a case ofglucagonoma in which treatment with dacarbazine was very effective (19). Because the plasma glucagon levels gradually increased in spite of the treatment with dacarbazine, we have treated the patient with subcutaneous injection of SMS 201-995 at a daily dose of 150 jig.…”

Section: Methodsmentioning

confidence: 99%

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.

Kubota¹,

Yamada²,

Kagimoto³

et al. 1994

J. Clin. Invest.

Self Cite

258

132

View full text Add to dashboard Cite

The presence of somatostatin receptors has been demonstrated in various endocrine tumors as well as in normal tissues. We recently have cloned five human somatostatin receptor subtypes (SSTRI-SSTR5). These mRNAs are expressed in a tissue-specific manner. In this study, we have determined the somatostatin receptor subtypes expressed in various endocrine tumors using a reverse transcriptase polymerase chain reaction method. In two cases of glucagonoma and its metastatic lymph nodes in one case, all the SSTR subtype mRNAs except SSTR5 mRNA were expressed. In four cases of insulinoma, SSTR1 and SSTR4 mRNAs were detected, but SSTR2 mRNA was not detected in one case and SSTR3 mRNA was not detected in two cases, indicating a heterogeneous expression of SSTR subtypes in insulinomas. Interestingly, SSTR3 mRNA, which is highly expressed in rat pancreatic islets, is not expressed in normal human pancreatic islets, while SSTR1, SSTR2, and SSTR4 mRNAs are expressed. In three cases of pheochromocytoma, SSTR1 and SSTR2 mRNAs were detected, showing an expression pattern identical to that of normal adrenal gland. In a carcinoid, SSTRI and SSTR4 mRNAs were detected. We have also found that human SSTR2 shows a high affinity for SMS 201-995, which has been used clinically for the treatment of endocrine tumors. Since SMS 201-995 was effective in the treatment of a patient with glucagonoma in which SSTR2 mRNA was present, but had no effect in a patient with carcinoid in which SSTR2 mRNA was not detected, this study suggests that the efficacy of SMS 201-995 may depend, at least in part, on the expression of SSTR2 in tumors. (J. Clin.

show abstract

Section: Methodsmentioning

confidence: 99%

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.

Kubota¹,

Yamada²,

Kagimoto³

et al. 1994

J. Clin. Invest.

Self Cite

258

132

View full text Add to dashboard Cite

show abstract

“…The effectiveness of standard chemotherapy is limited. The combination of streptozocin and 5‐fluorouracil with or without doxorubicin achieves some response in 69% of patients but limited improvement in survival [82]. An unusual exception to these poor results is the successful treatment of glucagonoma with dacarbazine [83], where even complete remission has been reported [84].…”

Section: Metastatic Diseasementioning

confidence: 99%

Current Concepts in Functioning Endocrine Tumors of the Pancreas

Proye

Lokey

2004

World j. surg.

View full text Add to dashboard Cite

Duodenal and pancreatic endocrine tumors are uncommon and their surgical treatment is often difficult. The management of these tumors has changed with recent advancements in tumor localization, intraoperative hormone measurements, standardized surgical techniques, and a better understanding of the genetic basis of multiple endocrine neoplasia syndrome. We present our experience with 191 endocrine tumors and elaborate the contemporary management of functioning duodenopancreatic endocrine tumors.

show abstract

A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome

Fujita

Seino

Ishida

et al. 1986

Cancer

View full text Add to dashboard Cite

A 46-year-old man had a 7-year history of severe rash, which was then diagnosed as necrolytic migratory erythema. H e had a weight loss of 6 kg, abnormal glucose tolerance test findings, anemia, glossitis, hair loss, and hypoproteinemia. Plasma amino acids levels were significantly decreased, and the fasting plasma glucagon (IRG) level was high at 5000 to 8000 pg/ml. Circulating IRG significantly increased after oral glucose loading, meal ingestion, and arginine infusion, and decreased with somatostatin infusion and insulin-induced hypoglycemia. No other gut or pancreatic hormone levels in plasma were elevated. Plasma IRG was eluted by gel-filtration, mainly in the position of true glucagon (MW 3500) by antiserum 30K.The rash was markedly improved after infusion of amino acids. Computerized tomography (a) scan and celiac angiography revealed a large pancreatic tumor with multiple liver and lymph node metastases. The pancreatic tumor was totally resected, and was identified as glucagonoma by immunohistochemical technique. Since the plasma IRG levels remained high after surgery, the patient received dimethyltriazenoimidazole carboxamide therapy. After several courses of this treatment, plasma IRG levels decreased to 1000 to 2000 pg/ml, and the hepatic metastases were remarkably diminished in size.Cancer 57: [860][861][862][863][864][865] 1986. LUCAGONOMA is a rare islet A-cell tumor of the pan-G creas. Becker et ul. ' first described this clinical phe-

show abstract

Successful Treatment of Metastatic Glucagonoma With Dacarbazine

Cited by 20 publications

References 3 publications

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.

Current Concepts in Functioning Endocrine Tumors of the Pancreas

A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome

Contact Info

Product

Resources

About